

7-5/2013/EU/WC-0138  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organisation  
(International Cell)

FDA Bhawan, Kotla Road,  
New Delhi-110002  
Dated

To

M/s Cipla Limited,  
Plot No 285, 286 and 287  
Bommasandra –Jigani Link Road  
Industrial area, KIADB, 4<sup>th</sup> Phase,  
Bengaluru-560105 Karnataka, India

09 JUL 2021

**SUB:-** Written Confirmation of M/s Cipla Limited, Plot No 285, 286 and 287, Bommasandra –Jigani Link Road, Industrial area, KIADB, 4<sup>th</sup> Phase, Bengaluru-560105 Karnataka, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application submitted to CDSCO, Bangalore office, and the recommendation received from DDC (I), Bangalore on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.



5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No	No. of Products	Date of Issue	Valid upto
1	22	09.08.2019	08.08.2022
2	01	01.04.2021	08.08.2022
3	01	09 JUL 2021	08.08.2022

Yours faithfully,

(Dr. V. G. Somani)  
Drugs Controller General (India)





GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

Annexure-3

CERTIFICATE NO. : WC-0138

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s Cipla Limited,  
Plot No 285, 286 and 287  
Bommasandra -Jigani Link Road  
Industrial area, KIADB, 4<sup>th</sup> Phase,  
Bengaluru-560105 Karnataka, India

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Pazopanib Hydrochloride IH	Manufacturing & Packing

ITEM(S) ONE (01) ONLY

The Written Confirmation remains valid until: 08.08.2022

  
Signature



09 JUL 2021